Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit 'ALL'

Nature Reviews Clinical Oncology

Volumn 15, Issue 4, 2018, Pages 218-

  Neelapu, Sattva S ^a   Tummala, Sudhakar ^a   Kebriaei, Partow ^a   Wierda, William ^a   Locke, Frederick L ^b   Lin, Yi ^c   Jain, Nitin ^a   Daver, Naval ^a   Gulbis, Alison M ^a   Adkins, Sherry ^a   Rezvani, Katayoun ^a   Hwu, Patrick ^a   Shpall, Elizabeth J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY AGENT; CHIMERIC ANTIGEN RECEPTOR; DEXAMETHASONE; INTERLEUKIN 6 ANTIBODY; JCAR 017; PREDNISOLONE; SILTUXIMAB; TISAGENLECLEUCEL T; TOCILIZUMAB; UNCLASSIFIED DRUG;

BRAIN DISEASE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CAR T CELL RELATED ENCEPHALOPATHY SYNDROME; CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY; CLINICAL RESEARCH; CORTICOSTEROID THERAPY; CYTOKINE RELEASE SYNDROME; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; LETTER; MALIGNANT NEOPLASM; NEUROTOXICITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY;

CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, CHIMERIC ANTIGEN;

EID: 85044213195     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2018.20     Document Type: Letter

References (17)

1. Teachey, D. T. et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat. Rev. Clin. Oncol. https://doi. org/10.1038.org/nrclinonc.2017.19 (2018).
2. Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy-Assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47-62 (2018).
3. Schuster, S. J. et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 130, 577 (2017).
4. Abramson, J. et al. High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood 130, 581 (2017).
5. Grupp, S. A. et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood 128, 221 (2016).
6. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531-2544 (2017).
7. Kebriaei, P. et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 126, 3363-3376 (2016).
8. Gilbert, M. J. Severe neurotoxicity in the phase 2 trial of JCAR015 in adult B-ALL (ROCKET study): analyses of patient, protocol and product attributes. in 32nd Annual SITC Meeting (National Harbor, MD, USA, 2017).
9. Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl Med. 7, 303ra139 (2015).
10. Fitzgerald, J. C. et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med. 45, e124-e131 (2017).
11. Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).
12. Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545-2554 (2017).
13. Ramos-Casals, M., Brito-Zeron, P., Lopez-Guillermo, A., Khamashta, M. A. & Bosch, X. Adult haemophagocytic syndrome. Lancet 383, 1503-1516 (2014).
14. Wang, Y. et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood 126, 2186-2192 (2015).
15. Horne, A. et al. How to treat involvement of the central nervous system in hemophagocytic lymphohistiocytosis? Curr. Treat. Opt. Neurol. 19, 3 (2017).
16. Santomasso, B. et al. Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells [abstract]. J. Clin. Oncol. 35 (Suppl.), 3019 (2017).
17. U.S. Food and Drug Administration. Yescarta prescribing information. FDA https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM581226.pdf (2017).